In PIONEER-AF [12] the DT of low dose rivaroxaban (15 mg daily) plus P2Y12 inhibitor resulted in less overall bleeding (16.8% versus 26.7%, HR 0.59, p < 0.001) and bleeding requiring medical attention (14.6% versus 22.6%, HR 0.61, p < 0.001) without any significant difference in the composite of cardiovascular death, MI, or stroke. This evidence concerns the gene P2RY12 and atrial fibrillation.